Elevation Oncology, Inc.

Elevation Oncology, Inc. Stock Forecast & Price Prediction

Live Elevation Oncology, Inc. Stock (ELEV) Price
$0.54

0

Ratings

  • Buy 0
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$0.54

P/E Ratio

-0.41

Volume Traded Today

$950,591

Dividend

Dividends not available for ELEV

52 Week High/low

5.83/0.36

Elevation Oncology, Inc. Market Cap

$35.5M

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $ELEV ๐Ÿ›‘

Before you buy ELEV you'll want to see this list of ten stocks that have huge potential. Want to see if ELEV made the cut? Enter your email below

ELEV Summary

Based on ratings from 0 stock analysts, the Elevation Oncology, Inc. stock price is expected to increase by 1288.89% in 12 months. This is calculated by using the average 12-month stock price forecast for Elevation Oncology, Inc.. The lowest target is $5 and the highest is $10. Please note analyst price targets are not guaranteed and could be missed completely.

ELEV Analyst Ratings

About 0 Wall Street analysts have assigned ELEV 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Elevation Oncology, Inc. to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ELEV. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

ELEV stock forecast by analyst

These are the latest 20 analyst ratings of ELEV.

Analyst/Firm

Rating

Price Target

Change

Date

Swayampakula Ramakanth
HC Wainwright & Co.

Buy

$6

Reiterates

Aug 7, 2024
Silvan Tuerkcan
JMP Securities

Market Outperform

$7

Reiterates

Jul 15, 2024
Silvan Tuerkcan
JMP Securities

Market Outperform

$7

Reiterates

Jun 28, 2024
Biren Amin
Piper Sandler

Overweight

$10

Initiates

May 31, 2024
Sudan Loganathan
Stephens & Co.

Overweight

$8

Initiates

May 14, 2024
Robert Driscoll
Wedbush

Outperform

$8

Reiterates

May 3, 2024
Swayampakula Ramakanth
HC Wainwright & Co.

Buy

$6

Reiterates

Apr 9, 2024
Swayampakula Ramakanth
HC Wainwright & Co.

Buy

$6

Reiterates

Mar 7, 2024
Silvan Tuerkcan
JMP Securities

Market Outperform

$7

Reiterates

Mar 7, 2024
Robert Driscoll
Wedbush

Outperform

$8

Maintains

Mar 7, 2024
Silvan Tuerkcan
JMP Securities

Market Outperform

$7

Initiates

Mar 1, 2024
Swayampakula Ramakanth
HC Wainwright & Co.

Buy

$6

Maintains

Feb 20, 2024
Robert Driscoll
Wedbush

Outperform

$5

Reiterates

Nov 6, 2023
Swayampakula Ramakanth
HC Wainwright & Co.

Buy

$1.5

Initiates

Sep 29, 2023
Robert Driscoll
Wedbush

Outperform

$6

Maintains

Jun 5, 2023
Andrew Berens
SVB Securities

Outperform

$8

Upgrade

May 30, 2023
Robert Driscoll
Wedbush

Outperform

$4

Reiterates

Mar 10, 2023
Andrew Berens
SVB Leerink

Market Perform

$1

Maintains

Jan 9, 2023
Anupam Rama
JP Morgan

Underweight


Downgrade

Nov 10, 2022
Andrew Berens
SVB Leerink

Market Perform

$2

Downgrade

Nov 7, 2022

ELEV Company Information

What They Do: Develops targeted cancer therapies for solid tumors.

Business Model: Elevation Oncology, Inc. operates by discovering and developing innovative cancer therapies, focusing on targeting specific molecular markers in tumors. The company generates revenue through licensing agreements, such as its collaboration with CSPC Megalith Biopharmaceutical Co., Ltd. for the development and commercialization of its lead candidate, EO-3021.

Other Information: Founded in 2019 and based in Boston, Massachusetts, Elevation Oncology aims to address significant unmet medical needs in oncology, particularly for patients with solid tumors. The company's strategic focus on antibody-drug conjugates positions it within the growing field of precision medicine.
ELEV
Elevation Oncology, Inc. (ELEV)

When did it IPO

2020

Staff Count

29

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Mr. Joseph J. Ferra Jr.

Market Cap

$35.5M

Elevation Oncology, Inc. (ELEV) Financial Data

In 2023, ELEV generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ELEV's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$0

Revenue From 2021

$0

0.00 %
From Previous Year

Revenue From 2022

$0

0.00 %
From Previous Year

Revenue From 2023

$0

0.00 %
From Previous Year
  • Revenue TTM $0
  • Operating Margin TTM 0.0%
  • Gross profit TTM $0
  • Return on assets TTM -22.1%
  • Return on equity TTM -51.9%
  • Profit Margin 0.0%
  • Book Value Per Share 1.48%
  • Market capitalisation $35.5M
  • Revenue for 2021 $0
  • Revenue for 2022 $0
  • Revenue for 2023 $0
  • EPS this year (TTM) $-0.68

Elevation Oncology, Inc. (ELEV) Latest News

News Image

Wed, 09 Oct 2024

Sentiment - POSITIVE

Source - GuruFocus

Summary - On September 30, 2024, Empery Asset Management acquired 4,000,000 shares of Elevation Oncology Inc at $0.5999 per share, increasing its stake in the biotechnology firm.

Why It Matters - Empery Asset Management's purchase of 4 million shares in Elevation Oncology signals confidence in the company's future, potentially influencing market sentiment and stock performance.

News Image

Thu, 10 Oct 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - Elevation Oncology (ELEV) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating increased optimism about its earnings prospects.

Why It Matters - Elevation Oncology's upgrade to a Zacks Rank #1 signals strong earnings potential, likely boosting investor confidence and driving stock price upward.

News Image

Mon, 23 Sep 2024

Sentiment - NEUTRAL

Source - PRNewsWire

Summary - Elevation Oncology's EO-3021 received FDA Fast Track designation for treating advanced gastric and gastroesophageal junction cancer, targeting patients with Claudin 18.2 expression.

Why It Matters - FDA Fast Track designation for EO-3021 enhances Elevation Oncology's market position, potentially accelerating its drug development timeline and improving revenue prospects in a niche cancer treatment market.

News Image

Tue, 03 Sep 2024

Sentiment - NEUTRAL

Source - PRNewsWire

Summary - Elevation Oncology, Inc. (Nasdaq: ELEV) has made a key announcement regarding its focus on developing selective cancer therapies for solid tumors with unmet medical needs.

Why It Matters - Elevation Oncology's announcement could indicate advancements in cancer therapies, potentially impacting stock performance and investor sentiment in the biotech sector.

News Image

Fri, 09 Aug 2024

Sentiment - POSITIVE

Source - Seeking Alpha

Summary - Recent stock ideas highlight Easterly Government Properties as a reliable income source akin to Treasury bonds, while Bunge Global shows potential for market expansion despite a Q2 decline.

Why It Matters - Stocks with less coverage may present undervalued opportunities. Easterly Government Properties offers stable income, while Bunge Global's growth potential may attract long-term interest.

News Image

Tue, 06 Aug 2024

Sentiment - NEGATIVE

Source - Benzinga

Summary - Elevation Oncology Inc. (ELEV) shares fell after the company released initial data from its Phase 1 trial of EO-3021 for advanced solid tumors expressing Claudin 18.2.

Why It Matters - The decline in Elevation Oncology's stock reflects market concerns over the Phase 1 trial data for EO-3021, potentially impacting future funding and investor confidence.

...

ELEV Frequently asked questions

The highest forecasted price for ELEV is $10 from Biren Amin at Piper Sandler.

The lowest forecasted price for ELEV is $5 from Robert Driscoll from Wedbush

The ELEV analyst ratings consensus are 0 buy ratings, 0 hold ratings, and 0 sell ratings.